PHGE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PHGE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-21), BiomX's share price is $0.3416. BiomX's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.07. Hence, BiomX's Price to Tangible Book Ratio of today is 5.10.
The historical rank and industry rank for BiomX's Price-to-Tangible-Book or its related term are showing as below:
During the past 6 years, BiomX's highest Price to Tangible Book Ratio was 5.29. The lowest was 0.27. And the median was 1.21.
A closely related ratio is called PB Ratio. As of today, BiomX's share price is $0.3416. BiomX's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.07. Hence, BiomX's P/B Ratio of today is 5.10.
The historical data trend for BiomX's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiomX Annual Data | |||||||||||||||
Trend | Jun18 | Jun19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Price-to-Tangible-Book | Get a 7-Day Free Trial | 1.21 | 2.73 | 1.03 | 0.27 | 4.18 |
BiomX Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 0.27 | 0.63 | 1.04 | 1.99 | 4.18 |
For the Biotechnology subindustry, BiomX's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, BiomX's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where BiomX's Price-to-Tangible-Book falls into.
BiomX's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Dec. 2023 ) |
= | 0.3416 | / | 0.067 | |
= | 5.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of BiomX's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Assaf Oron | officer: Chief Business Officer | C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Eddie Williams | director | 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Michael E. Dambach | director | 22 EINSTEIN STREET, FLOOR 4, NESS ZIONA L3 7414003 |
Jason M. Marks | director | C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807 |
Carl L Gordon | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Israel Biofund Gp Limited Partnership | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
Chidozie Ugwumba | 10 percent owner | 158 FILMORE STREET, DENVER CO 80206 |
Thomas Layton Walton | 10 percent owner | P.O. BOX 1860, BENTONVILLE AR 72712 |
Paul J Sekhri | director | C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588 |
Lynne Marie Sullivan | director | C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139 |
Marina Wolfson | officer: Principal Financial Officer | C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Jonathan Eitan Solomon | director, officer: Chief Executive Officer | C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Alan Charles Moses | director | C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Russell Greig | director | C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM |
Gbolahan Amusa | director | 17 STATE STREET 21 FLOOR, NEW YORK NY 10004 |
From GuruFocus
By PRNewswire PRNewswire • 10-03-2019
By PRNewswire PRNewswire • 10-28-2019
By PRNewswire PRNewswire • 07-28-2022
By PRNewswire PRNewswire • 10-23-2019
By PRNewswire PRNewswire • 07-17-2019
By PRNewswire PRNewswire • 05-10-2019
By PRNewswire PRNewswire • 07-17-2019
By PRNewswire PRNewswire • 03-13-2019
By GuruFocus Research GuruFocus Editor • 07-30-2021
By PRNewswire PRNewswire • 10-03-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.